CN111235130B - II类V型CRISPR蛋白CeCas12a及其在基因编辑的应用 - Google Patents

II类V型CRISPR蛋白CeCas12a及其在基因编辑的应用 Download PDF

Info

Publication number
CN111235130B
CN111235130B CN201911119880.3A CN201911119880A CN111235130B CN 111235130 B CN111235130 B CN 111235130B CN 201911119880 A CN201911119880 A CN 201911119880A CN 111235130 B CN111235130 B CN 111235130B
Authority
CN
China
Prior art keywords
lys
ile
asp
glu
cecas12a
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CN201911119880.3A
Other languages
English (en)
Other versions
CN111235130A (zh
Inventor
殷雷
陈鹏
周进
万义彬
刘欢
宋广济
雷骏
王宏健
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Wuhan University WHU
Original Assignee
Wuhan University WHU
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Wuhan University WHU filed Critical Wuhan University WHU
Priority to CN201911119880.3A priority Critical patent/CN111235130B/zh
Publication of CN111235130A publication Critical patent/CN111235130A/zh
Application granted granted Critical
Publication of CN111235130B publication Critical patent/CN111235130B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14Hydrolases (3)
    • C12N9/16Hydrolases (3) acting on ester bonds (3.1)
    • C12N9/22Ribonucleases RNAses, DNAses
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09Recombinant DNA-technology
    • C12N15/63Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09Recombinant DNA-technology
    • C12N15/87Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation
    • C12N15/90Stable introduction of foreign DNA into chromosome
    • C12N15/902Stable introduction of foreign DNA into chromosome using homologous recombination
    • C12N15/907Stable introduction of foreign DNA into chromosome using homologous recombination in mammalian cells
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2800/00Nucleic acids vectors
    • C12N2800/10Plasmid DNA
    • C12N2800/106Plasmid DNA for vertebrates
    • C12N2800/107Plasmid DNA for vertebrates for mammalian

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Biophysics (AREA)
  • Mycology (AREA)
  • Cell Biology (AREA)
  • Medicinal Chemistry (AREA)
  • Peptides Or Proteins (AREA)

Abstract

本发明属于生物医学领域,具体涉及本发明属于生物医学领域,具体涉及一种来自于Coprococcus eutactus细菌中的II类V型CRISPR蛋白CeCas12a及其应用。所述CeCas12a的氨基酸序列如SED ID NO.1所示,其编码核苷酸序列如SED ID NO.2所示。本发明首次在Coprococcus eutactus菌株中鉴定出具有基因编辑效应的II类V型CRISPR蛋白CeCas12a;所述CeCas12a能够在crRNA的介导下定点对原核生物和真核生物基因组进行基因编辑,CeCas12a的发现进一步扩大了基因编辑工具的种类,对基础科研和临床治疗具有十分重要的作用。

Description

II类V型CRISPR蛋白CeCas12a及其在基因编辑的应用
技术领域
本发明属于生物医学领域,具体涉及一种来自于Coprococcus eutactus细菌中的II类V 型CRISPR蛋白Cas12a,命名为CeCas12a,在基因编辑中的应用。
背景技术
自2013年以来,基因编辑技术取得了突破性进展,此项技术已经在基础科学研究、医药、临床、生物技术等许多领域引起了新的变革。除了具有代表性的Cas9系统之外,Cas12,又名Cpf1,作为又一种被发现的具有基因编辑效应的CRISPR系统新成员,极大的扩大了基因编辑系统靶点的可编辑范围,相比于Cas9系统,Cas12a所具有的加工前提RNA的功能,为其介导多基因编辑提供了相比与Cas9系统更为便捷高效的编辑能力。除此之外,相比于 Cas9的向导RNA,Cas12a的向导RNA组成更为简单,设计更为方便。
2015年,张峰团队首次发现了Cas9系统之外的另外一种具有基因编辑能力的新成员, Cas12a,又名Cpf1,将其划分到CRISPR系统2类V型中。相比于Cas9系统,Cas12a的编辑效率与Cas9的效率相当,在有些靶点低于Cas9。Cas12a的脱靶率极低,相比于Cas9脱靶率高的特性,Cas12a是一种安全的基因编辑工具。Cas12a在切割之后形成粘性末端,而 Cas9形成平末端,已有研究表明,Cas12a切割之后的粘性末端相比于Cas9的平末端而言,更容易发生同源重组修复,这也为基因的定点插入和修复提供了更好的工具。在向导RNA 的加工方面,Cas12a具有明显的优势,仅仅只需要Cas12a本身就能够完成对前提RNA的加工,而Cas9系统则需要RNaseIII的加工,这极大地促进Cas12a在多基因编辑上的应用。在 PAM的识别上,Cas12a识别5’-TTTN-3’或5’-KYTV-3’,Cas9则识别5’-NGG-3’。
因此,Cas12a作为一种新型基因编辑工具,与Cas9系统一道,为科学研究和疾病的治疗提供了有力的工具。基于对目前已有的Cas12a的研究,为应对将来各种情况下的基因编辑事件,发现更多的具有一定特性的Cas12a是一件具有重要意义的事情。
发明内容
本发明针对现有技术的不足,目的在于提供一种来自于Coprococcus eutactus细菌中的II 类V型CRISPR蛋白CeCas12a及其在基因编辑中的应用。
为实现上述发明目的,本发明所采用的技术方案为:
一种来自于Coprococcus eutactus细菌中的II类V型CRISPR蛋白CeCas12a,其氨基酸序列如SEQ ID NO.1所示。
上述方案中,所述CeCas12a识别的PAM序列为TTTV、TCTA、TTCA、或CTTA,更为优选的PAM序列为TTTV,所述V表示A、C、或G。
用于编辑蛋白CeCas12a氨基酸序列的基因,其核苷酸序列如SEQ ID NO.2所示。
上述CeCas12a在基因编辑中的应用。
上述CeCas12a在原核生物基因编辑中的应用。
上述CeCas12a在真核生物基因编辑中的应用。
上述CeCas12a在体外基因编辑中的应用。
本发明所述蛋白CeCas12a的氨基酸序列如下:
(1)原核细胞中:
NNNTNNSFEPFIGGNSVSKTLRNELRVGSEYTGKHIKECAIIAEDAVKAENQYIVKEMMDD FYRDFINRKLDALQGINWEQLFDIMKKAKLDKSNKVSKELDKIQESTRKEIVKIFSSDPIYK DMLKADMISKILPEYIVDKYGDAASRIEAVKVFYGFSGYFIDFWASRKNVFSDKNIASAIPH RIVNVNARIHLDNITAFNRIAEIAGDEVAGIAEDACAYLQNMSLEDVFTGACYGEFICQKDI DRYNNICGVINQHMNQYCQNKKISRSKFKMERLHKQILCRSESGFEIPIGFQTDGEVIDAIN SFSTILEEKDILDRLRTLSQEVTGYDMERIYVSSKAFESVSKYIDHKWDVIASSMYNYFSGA VRGKDDKKDAKIQTEIKKIKSCSLLDLKKLVDMYYKMDGMCLEHEATEYVAGITEILVDF NYKTFDMDDSVKMIQNEHMINEIKEYLDTYMSIYHWAKDFMIDELVDRDMEFYSELDEIY YDLSDIVPLYNKVRNYVTQKPYSQDKIKLNFGSPTLANGWSKSKEFDNNVVVLLRDEKIY LAILNVGNKPSKDIMAGEDRRRSDTDYKKMNYYLLPGASKTLPHVFISSNAWKKSHGIPD EIMYGYNQNKHLKSSPNFDLEFCRKLIDYYKECIDSYPNYQIFNFKFAATETYNDISEFYKD VERQGYKIEWSYISEDDINQMDRDGQIYLFQIYNKDFAPNSKGMQNLHTLYLKNIFSEENL SDVVIKLNGEAELFFRKSSIQHKRGHKKGSVLVNKTYKTTEKTENGQGEIEVIESVPDQCY LELVKYWSEGGVGQLSEEASKYKDKVSHYAATMDIVKDRRYTEDKFFIHMPITINFKADN RNNVNEKVLKFIAENDDLHVIGIDRGERNLLYVSVIDSRGRIVEQKSFNIVENYESSKNVIR RHDYKGKLVNKEHYRNEARKSWKEIGKIKEIKEGYLSQVIHEISKLVLKYNAIIVMEDLNY GFKRGRFKVERQVYQKFETMLINKLAYLVDKSRAVDEPGGLLKGYQLTYVPDNLGELGSQ CGIIFYVPAAYTSKIDPVTGFVDVFDFKAYSNAEARLDFINKLDCIRYDASRNKFEIAFDYGN FRTHHTTLAKTSWTIFIHGDRIKKERGSYGWKDEIIDIEARIRKLFEDTDIEYADGHNLIGDI NELESPIQKKFVGELFDIIRFTVQLRNSKSEKYDGTEKEYDKIISPVMDEEGVFFTTDSYIRA DGTELPKDADANGAYCIALKGLYDVLAVKKYWKEGEKFDRKLLAITNYNWFDFIQNRRF
(2)真核细胞中:
PKKKRKVNNNTNNSFEPFIGGNSVSKTLRNELRVGSEYTGKHIKECAIIAEDAVKAENQYIV KEMMDDFYRDFINRKLDALQGINWEQLFDIMKKAKLDKSNKVSKELDKIQESTRKEIVKIF SSDPIYKDMLKADMISKILPEYIVDKYGDAASRIEAVKVFYGFSGYFIDFWASRKNVFSDKN IASAIPHRIVNVNARIHLDNITAFNRIAEIAGDEVAGIAEDACAYLQNMSLEDVFTGACYGEF ICQKDIDRYNNICGVINQHMNQYCQNKKISRSKFKMERLHKQILCRSESGFEIPIGFQTDGE VIDAINSFSTILEEKDILDRLRTLSQEVTGYDMERIYVSSKAFESVSKYIDHKWDVIASSMY NYFSGAVRGKDDKKDAKIQTEIKKIKSCSLLDLKKLVDMYYKMDGMCLEHEATEYVAGIT EILVDFNYKTFDMDDSVKMIQNEHMINEIKEYLDTYMSIYHWAKDFMIDELVDRDMEFYS ELDEIYYDLSDIVPLYNKVRNYVTQKPYSQDKIKLNFGSPTLANGWSKSKEFDNNVVVLLR DEKIYLAILNVGNKPSKDIMAGEDRRRSDTDYKKMNYYLLPGASKTLPHVFISSNAWKKS HGIPDEIMYGYNQNKHLKSSPNFDLEFCRKLIDYYKECIDSYPNYQIFNFKFAATETYNDISE FYKDVERQGYKIEWSYISEDDINQMDRDGQIYLFQIYNKDFAPNSKGMQNLHTLYLKNIFS EENLSDVVIKLNGEAELFFRKSSIQHKRGHKKGSVLVNKTYKTTEKTENGQGEIEVIESVPD QCYLELVKYWSEGGVGQLSEEASKYKDKVSHYAATMDIVKDRRYTEDKFFIHMPITINFK ADNRNNVNEKVLKFIAENDDLHVIGIDRGERNLLYVSVIDSRGRIVEQKSFNIVENYESSKN VIRRHDYKGKLVNKEHYRNEARKSWKEIGKIKEIKEGYLSQVIHEISKLVLKYNAIIVMEDL NYGFKRGRFKVERQVYQKFETMLINKLAYLVDKSRAVDEPGGLLKGYQLTYVPDNLGEL GSQCGIIFYVPAAYTSKIDPVTGFVDVFDFKAYSNAEARLDFINKLDCIRYDASRNKFEIAFD YGNFRTHHTTLAKTSWTIFIHGDRIKKERGSYGWKDEIIDIEARIRKLFEDTDIEYADGHNLI GDINELESPIQKKFVGELFDIIRFTVQLRNSKSEKYDGTEKEYDKIISPVMDEEGVFFTTDSYI RADGTELPKDADANGAYCIALKGLYDVLAVKKYWKEGEKFDRKLLAITNYNWFDFIQNR RFKRPAATKKAGQAKKKKGSYPYDVPDYAYPYDVPDYAYPYDVPDYA
其中在CeCas12a蛋白氨基酸序列的N端加入PKKKRKV序列(该序列为N端NLS入核序列),在CeCas12a蛋白氨基酸序列的C端加入KRPAATKKAGQAKKKK序列(该序列为C 端NLS入核序列),随后用GS序列连接YPYDVPDYAYPYDVPDYAYPYDVPDYA序列(该序列为3HA序列)。
编码本发明所述蛋白CeCas12a的核苷酸序列如下:
aacaacaacaccaacaacagcttcgagcccttcatcggcggcaacagcgtgagcaagaccctgcgcaacgagctgcgcgtgggcagcgagtacaccggcaag cacatcaaggagtgcgccatcatcgccgaggacgccgtgaaggccgagaaccagtacatcgtgaaggagatgatggacgacttctaccgcgacttcatcaaccgc aagctggacgccctgcagggcatcaactgggagcagctgttcgacatcatgaagaaggccaagctggacaagagcaacaaggtgagcaaggagctggacaag atccaggagagcacccgcaaggagatcgtgaagatcttcagcagcgaccccatctacaaggacatgctgaaggccgacatgatcagcaagatcctgcccgagta catcgtggacaagtacggcgacgccgccagccgcatcgaggccgtgaaggtgttctacggcttcagcggctacttcatcgacttctgggccagccgcaagaacgt gttcagcgacaagaacatcgccagcgccatcccccaccgcatcgtgaacgtgaacgcccgcatccacctggacaacatcaccgccttcaaccgcatcgccgagat cgccggcgacgaggtggccggcatcgccgaggacgcctgcgcctacctgcagaacatgagcctggaggacgtgttcaccggcgcctgctacggcgagttcatct gccagaaggacatcgaccgctacaacaacatctgcggcgtgatcaaccagcacatgaaccagtactgccagaacaagaagatcagccgcagcaagttcaagatg gagcgcctgcacaagcagatcctgtgccgcagcgagagcggcttcgagatccccatcggcttccagaccgacggcgaggtgatcgacgccatcaacagcttcag caccatcctggaggagaaggacatcctggaccgcctgcgcaccctgagccaggaggtgaccggctacgacatggagcgcatctacgtgagcagcaaggccttc gagagcgtgagcaagtacatcgaccacaagtgggacgtgatcgccagcagcatgtacaactacttcagcggcgccgtgcgcggcaaggacgacaagaaggac gccaagatccagaccgagatcaagaagatcaagagctgcagcctgctggacctgaagaagctggtggacatgtactacaagatggacggcatgtgcctggagca cgaggccaccgagtacgtggccggcatcaccgagatcctggtggacttcaactacaagaccttcgacatggacgacagcgtgaagatgatccagaacgagcacatgatcaacgagatcaaggagtacctggacacctacatgagcatctaccactgggccaaggacttcatgatcgacgagctggtggaccgcgacatggagttctacagc gagctggacgagatctactacgacctgagcgacatcgtgcccctgtacaacaaggtgcgcaactacgtgacccagaagccctacagccaggacaagatcaagct gaacttcggcagccccaccctggccaacggctggagcaagagcaaggagttcgacaacaacgtggtggtgctgctgcgcgacgagaagatctacctggccatcc tgaacgtgggcaacaagcccagcaaggacatcatggccggcgaggaccgccgccgcagcgacaccgactacaagaagatgaactactacctgctgcccggcg ccagcaagaccctgccccacgtgttcatcagcagcaacgcctggaagaagagccacggcatccccgacgagatcatgtacggctacaaccagaacaagcacctg aagagcagccccaacttcgacctggagttctgccgcaagctgatcgactactacaaggagtgcatcgacagctaccccaactaccagatcttcaacttcaagttcgc cgccaccgagacctacaacgacatcagcgagttctacaaggacgtggagcgccagggctacaagatcgagtggagctacatcagcgaggacgacatcaaccag atggaccgcgacggccagatctacctgttccagatctacaacaaggacttcgcccccaacagcaagggcatgcagaacctgcacaccctgtacctgaagaacatct tcagcgaggagaacctgagcgacgtggtgatcaagctgaacggcgaggccgagctgttcttccgcaagagcagcatccagcacaagcgcggccacaagaagg gcagcgtgctggtgaacaagacctacaagaccaccgagaagaccgagaacggccagggcgagatcgaggtgatcgagagcgtgcccgaccagtgctacctgg agctggtgaagtactggagcgagggcggcgtgggccagctgagcgaggaggccagcaagtacaaggacaaggtgagccactacgccgccaccatggacatc gtgaaggaccgccgctacaccgaggacaagttcttcatccacatgcccatcaccatcaacttcaaggccgacaaccgcaacaacgtgaacgagaaggtgctgaag ttcatcgccgagaacgacgacctgcacgtgatcggcatcgaccgcggcgagcgcaacctgctgtacgtgagcgtgatcgacagccgcggccgcatcgtggagca gaagagcttcaacatcgtggagaactacgagagcagcaagaacgtgatccgccgccacgactacaagggcaagctggtgaacaaggagcactaccgcaacgag gcccgcaagagctggaaggagatcggcaagatcaaggagatcaaggagggctacctgagccaggtgatccacgagatcagcaagctggtgctgaagtacaacg ccatcatcgtgatggaggacctgaactacggcttcaagcgcggccgcttcaaggtggagcgccaggtgtaccagaagttcgagaccatgctgatcaacaagctgg cctacctggtggacaagagccgcgccgtggacgagcccggcggcctgctgaagggctaccagctgacctacgtgcccgacaacctgggcgagctgggcagcc agtgcggcatcatcttctacgtgcccgccgcctacaccagcaagatcgaccccgtgaccggcttcgtggacgtgttcgacttcaaggcctacagcaacgccgaggc ccgcctggacttcatcaacaagctggactgcatccgctacgacgccagccgcaacaagttcgagatcgccttcgactacggcaacttccgcacccaccacaccacc ctggccaagaccagctggaccatcttcatccacggcgaccgcatcaagaaggagcgcggcagctacggctggaaggacgagatcatcgacatcgaggcccgca tccgcaagctgttcgaggacaccgacatcgagtacgccgacggccacaacctgatcggcgacatcaacgagctggagagccccatccagaagaagttcgtgggc gagctgttcgacatcatccgcttcaccgtgcagctgcgcaacagcaagagcgagaagtacgacggcaccgagaaggagtacgacaagatcatcagccccgtgat ggacgaggagggcgtgttcttcaccaccgacagctacatccgcgccgacggcaccgagctgcccaaggacgccgacgccaacggcgcctactgcatcgccctg aagggcctgtacgacgtgctggccgtgaagaagtactggaaggagggcgagaagttcgaccgcaagctgctggccatcaccaactacaactggttcgacttcatc cagaaccgccgcttc
本发明中Coprococcus eutactus菌株基因组中部分CRISPR array如图2所示,基因组中黑体显示CRISPR array序列为“ATCTACAACAGTAGAAATTATCTATAGGTTCTTGG”,因此,使用的crRNA direct repeat序列为5’-AATTTCTACTGTTGTAGAT-3’。
本发明的有益效果:本发明首次在Coprococcus eutactus菌株中鉴定出具有基因编辑效应的II类V型CRISPR蛋白,命名为CeCas12a;所述CeCas12a能够在crRNA的介导下定点对原核生物和真核生物基因组进行基因编辑,CeCas12a的发现进一步扩大了基因编辑工具的种类,同时也为后续各种不同情况的基因编辑提供了重要的备选工具,对基础科研和临床治疗具有十分重要的作用。
附图说明
图1为Coprococcus eutactus菌株CRISPR array及crRNA direct repeat图示。
图2为Coprococcus eutactus菌株基因组中存在的部分CRISPR array示意图。
图3为体外切割EGFP片段靶点示意图。
图4为原核表达CeCas12a之后,体外切割实验,S表示substrate;P表示product。
图5为体外实验验证CeCas12a的PAM,S表示substrate;P表示product。
图6为体内验证CeCas12a基因编辑,S表示substrate;P表示product。
图7为体内验证CeCas12a利用加工前提crRNA来同时编辑多个基因。
图8为深度测序验证CeCas12a的脱靶率。
具体实施方式
为了更好地理解本发明,下面结合实施例进一步阐明本发明的内容,但本发明的内容不仅仅局限于下面的实施例。
实施例1
CeCas12a体外不同时间梯度切割实验,包括以下实验步骤:
(1)CeCas12a蛋白的表达与纯化:将CeCas12a基因序列合成到pet28a表达载体上,且在C末端加上6His标签,随后将合成好的质粒转化到E.Coli Rosseta 2(DE3)表达菌株中,挑取单克隆,小量表达检测确定蛋白表达后进行蛋白的大量表达与纯化;重组蛋白依次经过 Ni柱亲和层析,heparin柱层析,superdex 200分子筛纯化后,保存在buffer(10mMTris-HCl, 200mM NaCl,1mM MgCl)中,并冻存于-80℃备用;
(2)使用crRNA direct repeat序列为:5’-AATTTCTACTGTTGTAGAT-3’,在体外转录获得crRNA;将步骤(1)所得CeCas12a蛋白与crRNA混合得到CeCas12a-crRNA复合物;
(3)取100nM CeCas12a-crRNA复合物与300ng线性化的底物(图4所示)混匀,37℃孵育分别孵育0,1,2,5,10min后,加入适量蛋白酶K,58℃消化60min,跑2%琼脂糖胶,结果如图4所示,CeCas12a具有良好的体外切割能力。
实施例2
CeCas12a识别PAM的确定
(1)设计NNNN四个位置随机组合的上下游引物(N表示A、G、C、T),以EGFP片段作为模板,采用overlap PCR方法进行PCR,得到256种带有不同PAM序列,但spacer 序列一样的1.1kb的线性化底物;
(2)取100nM CeCas12a-crRNA复合物与300ng线性化的底物混匀,37℃孵育分别孵育10min后,加入适量蛋白酶K,58℃消化60min,跑2%琼脂糖胶,部分结果如图5所示,CeCas12a能够识别不同的PAM:TTTA、TCTA、TTCA、CTTA,但最优PAM为TTTV(V 表示A,C,G)。
实施例3
CeCas12a在哺乳动物细胞内不同基因的编辑:
(1)构建CeCas12a真核表达质粒:将CeCas12a基因序列合成到pet28a表达载体上构建CeCas12a真核表达质粒;
(2)在哺乳动物细胞中,以293T细胞为例选择TRAC、TRBC、B2M、CTLA4、PD1五个基因,分别以这五个基因为目标,构建5个由U6启动子启动转录的U6-crRNA spacer真核表达质粒;
(3)分别针对这五个基因的切割靶点附近设计surveyor primer,并验证PCR引物的特异性;
(4)消化293T细胞,适当浓度铺24孔板,每孔500ul;
(5)24孔板共转CeCas12a真核表达质粒(700ng)和U6-crRNA spacer真核表达质粒(300ng),48h后裂解细胞,取1ul裂解液作为模板、以步骤(3)设计的surveyor primer引物进行PCR,纯化PCR产物;
(6)取300ng PCR产物与1ul 10XT7EI buffer混匀,按以下PCR程序进行复性95℃10min,95℃至85℃-2℃/S,85℃到25℃-0.25℃/S,25℃持续1min,复性之后产物加入 1ulT7EI,37℃酶切20min,跑2%琼脂糖胶,结果如图6所示在TRAC、TRBC、B2M、CTLA4、 PD1能够进行基因编辑,编辑效率分别为12%,18%,31%,26%,19%(本案例中的四个基因只是作为代表进行列举)。
实施例4
CeCas12a在哺乳动物细胞内进行多基因编辑:
(1)选取并设计由一个U6启动子启动转录形成pre-crRNA array,pre-crRNA为同时包括TRAC、TRBC、B2M、CTLA4四个基因的crRNA序列;
(2)切割靶点附近设计surveyor primer,并验证PCR引物的特异性;
(3)消化293T细胞,适当浓度铺24孔板,每孔500ul;
(4)24孔板共转CeCas12a真核表达质粒(700ng)和步骤(1)获得的包含TRAC、TRBC、B2M、CTLA4四个基因的U6-crRNA spacer真核表达质粒(300ng),48h后裂解细胞,取1ul 裂解液作为模板、以步骤(3)设计的surveyor primer引物进行PCR,纯化PCR产物;
(5)取300ngPCR产物与1ul 10XT7EI buffer混匀,按以下PCR程序进行复性95℃10min,95℃至85℃-2℃/S,85℃到25℃-0.25℃/S,25℃持续1min。
(6)复性之后产物加入1ul T7EI,37℃酶切20min,跑2%琼脂糖胶,结果如图7所示,采用灰度分析可得对TRAC、TRBC、B2M、CTLA4四个基因靶点的切割效率分别为15%,25%, 45%,45%。
实施例5
(1)选取DNMT1、HBB、IL12A、POLQ、B2M 5个基因5个靶点进行脱靶分析,用软件(http://www.rgenome.net/cas-offinder/)预测了41个脱靶位点,并设计相应引物。
(2)24孔板共转As/Lb/CeCas12a真核表达质粒(700ng)和U6-crRNA spacer真核表达质粒(300ng),48h后裂解细胞,取1ul裂解液作为模板并采用1)中设计的引物进行扩增,然后纯化,进行二代测序,统计结构如图8所示,AsCas12a,LbCas12a,CeCas12a都具有很低的脱靶率,但CeCas12a相比于AsCas12a,LbCas12a具有更低的脱靶率。
显然,上述实施例仅仅是为清楚地说明所作的实例,而并非对实施方式的限制。对于所属领域的普通技术人员来说,在上述说明的基础上还可以做出其它不同形式的变化或变动。这里无需也无法对所有的实施方式予以穷举。而因此所引申的显而易见的变化或变动仍处于本发明创造的保护范围之内。
序列表
<110>武汉大学
<120>II类V型CRISPR 蛋白CeCas12a及其用于基因编辑的应用
<160>2
<210> 1
<211> 1286
<212> PRT
<213>Coprococcus eutactus细菌
<400>1
Asn Asn Asn Thr Asn Asn Ser Phe Glu Pro Phe Ile Gly Gly Asn Ser
1 5 10 15
Val Ser Lys Thr Leu Arg Asn Glu Leu Arg Val Gly Ser Glu Tyr Thr
20 25 30
Gly Lys His Ile Lys Glu Cys Ala Ile Ile Ala Glu Asp Ala Val Lys
35 40 45
Ala Glu Asn Gln Tyr Ile Val Lys Glu Met Met Asp Asp Phe Tyr Arg
50 55 60
Asp Phe Ile Asn Arg Lys Leu Asp Ala Leu Gln Gly Ile Asn Trp Glu
65 70 75 80
Gln Leu Phe Asp Ile Met Lys Lys Ala Lys Leu Asp Lys Ser Asn Lys
85 90 95
Val Ser Lys Glu Leu Asp Lys Ile Gln Glu Ser Thr Arg Lys Glu Ile
100 105 110
Val Lys Ile Phe Ser Ser Asp Pro Ile Tyr Lys Asp Met Leu Lys Ala
115 120 125
Asp Met Ile Ser Lys Ile Leu Pro Glu Tyr Ile Val Asp Lys Tyr Gly
130 135 140
Asp Ala Ala Ser Arg Ile Glu Ala Val Lys Val Phe Tyr Gly Phe Ser
145 150 155 160
Gly Tyr Phe Ile Asp Phe Trp Ala Ser Arg Lys Asn Val Phe Ser Asp
165 170 175
Lys Asn Ile Ala Ser Ala Ile Pro His Arg Ile Val Asn Val Asn Ala
180 185 190
Arg Ile His Leu Asp Asn Ile Thr Ala Phe Asn Arg Ile Ala Glu Ile
195 200 205
Ala Gly Asp Glu Val Ala Gly Ile Ala Glu Asp Ala Cys Ala Tyr Leu
210 215 220
Gln Asn Met Ser Leu Glu Asp Val Phe Thr Gly Ala Cys Tyr Gly Glu
225 230 235 240
Phe Ile Cys Gln Lys Asp Ile Asp Arg Tyr Asn Asn Ile Cys Gly Val
245 250 255
Ile Asn Gln His Met Asn Gln Tyr Cys Gln Asn Lys Lys Ile Ser Arg
260 265 270
Ser Lys Phe Lys Met Glu Arg Leu His Lys Gln Ile Leu Cys Arg Ser
275 280 285
Glu Ser Gly Phe Glu Ile Pro Ile Gly Phe Gln Thr Asp Gly Glu Val
290 295 300
Ile Asp Ala Ile Asn Ser Phe Ser Thr Ile Leu Glu Glu Lys Asp Ile
305 310 315 320
Leu Asp Arg Leu Arg Thr Leu Ser Gln Glu Val Thr Gly Tyr Asp Met
325 330 335
Glu Arg Ile Tyr Val Ser Ser Lys Ala Phe Glu Ser Val Ser Lys Tyr
340 345 350
Ile Asp His Lys Trp Asp Val Ile Ala Ser Ser Met Tyr Asn Tyr Phe
355 360 365
Ser Gly Ala Val Arg Gly Lys Asp Asp Lys Lys Asp Ala Lys Ile Gln
370 375 380
Thr Glu Ile Lys Lys Ile Lys Ser Cys Ser Leu Leu Asp Leu Lys Lys
385 390 395 400
Leu Val Asp Met Tyr Tyr Lys Met Asp Gly Met Cys Leu Glu His Glu
405 410 415
Ala Thr Glu Tyr Val Ala Gly Ile Thr Glu Ile Leu Val Asp Phe Asn
420 425 430
Tyr Lys Thr Phe Asp Met Asp Asp Ser Val Lys Met Ile Gln Asn Glu
435 440 445
His Met Ile Asn Glu Ile Lys Glu Tyr Leu Asp Thr Tyr Met Ser Ile
450 455 460
Tyr His Trp Ala Lys Asp Phe Met Ile Asp Glu Leu Val Asp Arg Asp
465 470 475 480
Met Glu Phe Tyr Ser Glu Leu Asp Glu Ile Tyr Tyr Asp Leu Ser Asp
485 490 495
Ile Val Pro Leu Tyr Asn Lys Val Arg Asn Tyr Val Thr Gln Lys Pro
500 505 510
Tyr Ser Gln Asp Lys Ile Lys Leu Asn Phe Gly Ser Pro Thr Leu Ala
515 520 525
Asn Gly Trp Ser Lys Ser Lys Glu Phe Asp Asn Asn Val Val Val Leu
530 535 540
Leu Arg Asp Glu Lys Ile Tyr Leu Ala Ile Leu Asn Val Gly Asn Lys
545 550 555 560
Pro Ser Lys Asp Ile Met Ala Gly Glu Asp Arg Arg Arg Ser Asp Thr
565 570 575
Asp Tyr Lys Lys Met Asn Tyr Tyr Leu Leu Pro Gly Ala Ser Lys Thr
580 585 590
Leu Pro His Val Phe Ile Ser Ser Asn Ala Trp Lys Lys Ser His Gly
595 600 605
Ile Pro Asp Glu Ile Met Tyr Gly Tyr Asn Gln Asn Lys His Leu Lys
610 615 620
Ser Ser Pro Asn Phe Asp Leu Glu Phe Cys Arg Lys Leu Ile Asp Tyr
625 630 635 640
Tyr Lys Glu Cys Ile Asp Ser Tyr Pro Asn Tyr Gln Ile Phe Asn Phe
645 650 655
Lys Phe Ala Ala Thr Glu Thr Tyr Asn Asp Ile Ser Glu Phe Tyr Lys
660 665 670
Asp Val Glu Arg Gln Gly Tyr Lys Ile Glu Trp Ser Tyr Ile Ser Glu
675 680 685
Asp Asp Ile Asn Gln Met Asp Arg Asp Gly Gln Ile Tyr Leu Phe Gln
690 695 700
Ile Tyr Asn Lys Asp Phe Ala Pro Asn Ser Lys Gly Met Gln Asn Leu
705 710 715 720
His Thr Leu Tyr Leu Lys Asn Ile Phe Ser Glu Glu Asn Leu Ser Asp
725 730 735
Val Val Ile Lys Leu Asn Gly Glu Ala Glu Leu Phe Phe Arg Lys Ser
740 745 750
Ser Ile Gln His Lys Arg Gly His Lys Lys Gly Ser Val Leu Val Asn
755 760 765
Lys Thr Tyr Lys Thr Thr Glu Lys Thr Glu Asn Gly Gln Gly Glu Ile
770 775 780
Glu Val Ile Glu Ser Val Pro Asp Gln Cys Tyr Leu Glu Leu Val Lys
785 790 795 800
Tyr Trp Ser Glu Gly Gly Val Gly Gln Leu Ser Glu Glu Ala Ser Lys
805 810 815
Tyr Lys Asp Lys Val Ser His Tyr Ala Ala Thr Met Asp Ile Val Lys
820 825 830
Asp Arg Arg Tyr Thr Glu Asp Lys Phe Phe Ile His Met Pro Ile Thr
835 840 845
Ile Asn Phe Lys Ala Asp Asn Arg Asn Asn Val Asn Glu Lys Val Leu
850 855 860
Lys Phe Ile Ala Glu Asn Asp Asp Leu His Val Ile Gly Ile Asp Arg
865 870 875 880
Gly Glu Arg Asn Leu Leu Tyr Val Ser Val Ile Asp Ser Arg Gly Arg
885 890 895
Ile Val Glu Gln Lys Ser Phe Asn Ile Val Glu Asn Tyr Glu Ser Ser
900 905 910
Lys Asn Val Ile Arg Arg His Asp Tyr Lys Gly Lys Leu Val Asn Lys
915 920 925
Glu His Tyr Arg Asn Glu Ala Arg Lys Ser Trp Lys Glu Ile Gly Lys
930 935 940
Ile Lys Glu Ile Lys Glu Gly Tyr Leu Ser Gln Val Ile His Glu Ile
945 950 955 960
Ser Lys Leu Val Leu Lys Tyr Asn Ala Ile Ile Val Met Glu Asp Leu
965 970 975
Asn Tyr Gly Phe Lys Arg Gly Arg Phe Lys Val Glu Arg Gln Val Tyr
980 985 990
Gln Lys Phe Glu Thr Met Leu Ile Asn Lys Leu Ala Tyr Leu Val Asp
995 1000 1005
Lys Ser Arg Ala Val Asp Glu Pro Gly Gly Leu Leu Lys Gly Tyr Gln
1010 1015 1020
Leu Thr Tyr Val Pro Asp Asn Leu Gly Glu Leu Gly Ser Gln Cys Gly
1025 1030 1035 1040
Ile Ile Phe Tyr Val Pro Ala Ala Tyr Thr Ser Lys Ile Asp Pro Val
1045 1050 1055
Thr Gly Phe Val Asp Val Phe Asp Phe Lys Ala Tyr Ser Asn Ala Glu
1060 1065 1070
Ala Arg Leu Asp Phe Ile Asn Lys Leu Asp Cys Ile Arg Tyr Asp Ala
1075 1080 1085
Ser Arg Asn Lys Phe Glu Ile Ala Phe Asp Tyr Gly Asn Phe Arg Thr
1090 1095 1100
His His Thr Thr Leu Ala Lys Thr Ser Trp Thr Ile Phe Ile His Gly
1105 1110 1115 1120
Asp Arg Ile Lys Lys Glu Arg Gly Ser Tyr Gly Trp Lys Asp Glu Ile
1125 1130 1135
Ile Asp Ile Glu Ala Arg Ile Arg Lys Leu Phe Glu Asp Thr Asp Ile
1140 1145 1150
Glu Tyr Ala Asp Gly His Asn Leu Ile Gly Asp Ile Asn Glu Leu Glu
1155 1160 1165
Ser Pro Ile Gln Lys Lys Phe Val Gly Glu Leu Phe Asp Ile Ile Arg
1170 1175 1180
Phe Thr Val Gln Leu Arg Asn Ser Lys Ser Glu Lys Tyr Asp Gly Thr
1185 1190 1195 1200
Glu Lys Glu Tyr Asp Lys Ile Ile Ser Pro Val Met Asp Glu Glu Gly
1205 1210 1215
Val Phe Phe Thr Thr Asp Ser Tyr Ile Arg Ala Asp Gly Thr Glu Leu
1220 1225 1230
Pro Lys Asp Ala Asp Ala Asn Gly Ala Tyr Cys Ile Ala Leu Lys Gly
1235 1240 1245
Leu Tyr Asp Val Leu Ala Val Lys Lys Tyr Trp Lys Glu Gly Glu Lys
1250 1255 1260
Phe Asp Arg Lys Leu Leu Ala Ile Thr Asn Tyr Asn Trp Phe Asp Phe
1265 1270 1275 1280
Ile Gln Asn Arg Arg Phe
1285
<210> 2
<211> 3858bp
<212> DNA
<213>Coprococcus eutactus细菌
<400>2
aacaacaaca ccaacaacag cttcgagccc ttcatcggcg gcaacagcgt gagcaagacc 60
ctgcgcaacg agctgcgcgt gggcagcgag tacaccggca agcacatcaa ggagtgcgcc 120
atcatcgccg aggacgccgt gaaggccgag aaccagtaca tcgtgaagga gatgatggac 180
gacttctacc gcgacttcat caaccgcaag ctggacgccc tgcagggcat caactgggag 240
cagctgttcg acatcatgaa gaaggccaag ctggacaaga gcaacaaggt gagcaaggag 300
ctggacaaga tccaggagag cacccgcaag gagatcgtga agatcttcag cagcgacccc 360
atctacaagg acatgctgaa ggccgacatg atcagcaaga tcctgcccga gtacatcgtg 420
gacaagtacg gcgacgccgc cagccgcatc gaggccgtga aggtgttcta cggcttcagc 480
ggctacttca tcgacttctg ggccagccgc aagaacgtgt tcagcgacaa gaacatcgcc 540
agcgccatcc cccaccgcat cgtgaacgtg aacgcccgca tccacctgga caacatcacc 600
gccttcaacc gcatcgccga gatcgccggc gacgaggtgg ccggcatcgc cgaggacgcc 660
tgcgcctacc tgcagaacat gagcctggag gacgtgttca ccggcgcctg ctacggcgag 720
ttcatctgcc agaaggacat cgaccgctac aacaacatct gcggcgtgat caaccagcac 780
atgaaccagt actgccagaa caagaagatc agccgcagca agttcaagat ggagcgcctg 840
cacaagcaga tcctgtgccg cagcgagagc ggcttcgaga tccccatcgg cttccagacc 900
gacggcgagg tgatcgacgc catcaacagc ttcagcacca tcctggagga gaaggacatc 960
ctggaccgcc tgcgcaccct gagccaggag gtgaccggct acgacatgga gcgcatctac 1020
gtgagcagca aggccttcga gagcgtgagc aagtacatcg accacaagtg ggacgtgatc 1080
gccagcagca tgtacaacta cttcagcggc gccgtgcgcg gcaaggacga caagaaggac 1140
gccaagatcc agaccgagat caagaagatc aagagctgca gcctgctgga cctgaagaag 1200
ctggtggaca tgtactacaa gatggacggc atgtgcctgg agcacgaggc caccgagtac 1260
gtggccggca tcaccgagat cctggtggac ttcaactaca agaccttcga catggacgac 1320
agcgtgaaga tgatccagaa cgagcacatg atcaacgaga tcaaggagta cctggacacc 1380
tacatgagca tctaccactg ggccaaggac ttcatgatcg acgagctggt ggaccgcgac 1440
atggagttct acagcgagct ggacgagatc tactacgacc tgagcgacat cgtgcccctg 1500
tacaacaagg tgcgcaacta cgtgacccag aagccctaca gccaggacaa gatcaagctg 1560
aacttcggca gccccaccct ggccaacggc tggagcaaga gcaaggagtt cgacaacaac 1620
gtggtggtgc tgctgcgcga cgagaagatc tacctggcca tcctgaacgt gggcaacaag 1680
cccagcaagg acatcatggc cggcgaggac cgccgccgca gcgacaccga ctacaagaag 1740
atgaactact acctgctgcc cggcgccagc aagaccctgc cccacgtgtt catcagcagc 1800
aacgcctgga agaagagcca cggcatcccc gacgagatca tgtacggcta caaccagaac 1860
aagcacctga agagcagccc caacttcgac ctggagttct gccgcaagct gatcgactac 1920
tacaaggagt gcatcgacag ctaccccaac taccagatct tcaacttcaa gttcgccgcc 1980
accgagacct acaacgacat cagcgagttc tacaaggacg tggagcgcca gggctacaag 2040
atcgagtgga gctacatcag cgaggacgac atcaaccaga tggaccgcga cggccagatc 2100
tacctgttcc agatctacaa caaggacttc gcccccaaca gcaagggcat gcagaacctg 2160
cacaccctgt acctgaagaa catcttcagc gaggagaacc tgagcgacgt ggtgatcaag 2220
ctgaacggcg aggccgagct gttcttccgc aagagcagca tccagcacaa gcgcggccac 2280
aagaagggca gcgtgctggt gaacaagacc tacaagacca ccgagaagac cgagaacggc 2340
cagggcgaga tcgaggtgat cgagagcgtg cccgaccagt gctacctgga gctggtgaag 2400
tactggagcg agggcggcgt gggccagctg agcgaggagg ccagcaagta caaggacaag 2460
gtgagccact acgccgccac catggacatc gtgaaggacc gccgctacac cgaggacaag 2520
ttcttcatcc acatgcccat caccatcaac ttcaaggccg acaaccgcaa caacgtgaac 2580
gagaaggtgc tgaagttcat cgccgagaac gacgacctgc acgtgatcgg catcgaccgc 2640
ggcgagcgca acctgctgta cgtgagcgtg atcgacagcc gcggccgcat cgtggagcag 2700
aagagcttca acatcgtgga gaactacgag agcagcaaga acgtgatccg ccgccacgac 2760
tacaagggca agctggtgaa caaggagcac taccgcaacg aggcccgcaa gagctggaag 2820
gagatcggca agatcaagga gatcaaggag ggctacctga gccaggtgat ccacgagatc 2880
agcaagctgg tgctgaagta caacgccatc atcgtgatgg aggacctgaa ctacggcttc 2940
aagcgcggcc gcttcaaggt ggagcgccag gtgtaccaga agttcgagac catgctgatc 3000
aacaagctgg cctacctggt ggacaagagc cgcgccgtgg acgagcccgg cggcctgctg 3060
aagggctacc agctgaccta cgtgcccgac aacctgggcg agctgggcag ccagtgcggc 3120
atcatcttct acgtgcccgc cgcctacacc agcaagatcg accccgtgac cggcttcgtg 3180
gacgtgttcg acttcaaggc ctacagcaac gccgaggccc gcctggactt catcaacaag 3240
ctggactgca tccgctacga cgccagccgc aacaagttcg agatcgcctt cgactacggc 3300
aacttccgca cccaccacac caccctggcc aagaccagct ggaccatctt catccacggc 3360
gaccgcatca agaaggagcg cggcagctac ggctggaagg acgagatcat cgacatcgag 3420
gcccgcatcc gcaagctgtt cgaggacacc gacatcgagt acgccgacgg ccacaacctg 3480
atcggcgaca tcaacgagct ggagagcccc atccagaaga agttcgtggg cgagctgttc 3540
gacatcatcc gcttcaccgt gcagctgcgc aacagcaaga gcgagaagta cgacggcacc 3600
gagaaggagt acgacaagat catcagcccc gtgatggacg aggagggcgt gttcttcacc 3660
accgacagct acatccgcgc cgacggcacc gagctgccca aggacgccga cgccaacggc 3720
gcctactgca tcgccctgaa gggcctgtac gacgtgctgg ccgtgaagaa gtactggaag 3780
gagggcgaga agttcgaccg caagctgctg gccatcacca actacaactg gttcgacttc 3840
atccagaacc gccgcttc 3858

Claims (1)

1.一种来自于Coprococcus eutactus细菌中的II类V型CRISPR蛋白CeCas12a在原核生物基因编辑、真核生物基因编辑、体外基因编辑中的应用,所述CeCas12a的氨基酸序列如SEQ ID NO.1所示,核苷酸序列如SEQ ID NO.2所示;所述CeCas12a识别的PAM序列为TTTV、TCTA、TTCA或CTTA,所述V表示A、C或G。
CN201911119880.3A 2019-11-15 2019-11-15 II类V型CRISPR蛋白CeCas12a及其在基因编辑的应用 Active CN111235130B (zh)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN201911119880.3A CN111235130B (zh) 2019-11-15 2019-11-15 II类V型CRISPR蛋白CeCas12a及其在基因编辑的应用

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CN201911119880.3A CN111235130B (zh) 2019-11-15 2019-11-15 II类V型CRISPR蛋白CeCas12a及其在基因编辑的应用

Publications (2)

Publication Number Publication Date
CN111235130A CN111235130A (zh) 2020-06-05
CN111235130B true CN111235130B (zh) 2022-11-25

Family

ID=70877733

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201911119880.3A Active CN111235130B (zh) 2019-11-15 2019-11-15 II类V型CRISPR蛋白CeCas12a及其在基因编辑的应用

Country Status (1)

Country Link
CN (1) CN111235130B (zh)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN111394337A (zh) * 2019-11-15 2020-07-10 武汉大学 II类V型CRISPR蛋白Lb2Cas12a及其在基因编辑的应用
US20230357796A1 (en) * 2019-11-27 2023-11-09 Danmarks Tekniske Universitet Constructs, compositions and methods thereof having improved genome editing efficiency and specificity
CN116676291B (zh) * 2022-08-22 2024-02-27 华中农业大学 核酸内切酶Genie scissor及其介导的基因编辑系统
WO2024089629A1 (en) * 2022-10-27 2024-05-02 Geneditbio Limited Cas12 protein, crispr-cas system and uses thereof
CN115786305A (zh) * 2022-11-03 2023-03-14 武汉大学 一种紧凑型编辑工具EbCas12a在基因编辑中的应用

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2016106236A1 (en) * 2014-12-23 2016-06-30 The Broad Institute Inc. Rna-targeting system

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN107406838A (zh) * 2014-11-06 2017-11-28 纳幕尔杜邦公司 Rna引导的内切核酸酶向细胞中的肽介导的递送
US9896696B2 (en) * 2016-02-15 2018-02-20 Benson Hill Biosystems, Inc. Compositions and methods for modifying genomes
EP3510151A4 (en) * 2016-09-09 2020-04-15 The Board of Trustees of the Leland Stanford Junior University HIGH-THROUGHPUT PRECISION GENE EDITING
GB201618507D0 (en) * 2016-11-02 2016-12-14 Stichting Voor De Technische Wetenschappen And Wageningen Univ Microbial genome editing
WO2018085644A1 (en) * 2016-11-03 2018-05-11 Youhealth Biotech, Limited Methods and compositions for cellular reprogramming
CN108690845B (zh) * 2017-04-10 2021-04-27 中国科学院动物研究所 基因组编辑系统和方法
AU2018370588B2 (en) * 2017-11-21 2022-09-08 Genkore Co. Ltd. Composition for Genome Editing Using Crispr/CPF1 System and Use Thereof
WO2019126562A1 (en) * 2017-12-22 2019-06-27 Bio-Rad Laboratories, Inc. Controlling phenotype of organisms with crispr/cas gene targeting
CN112020554A (zh) * 2018-02-23 2020-12-01 先锋国际良种公司 新颖cas9直系同源物
CN111394337A (zh) * 2019-11-15 2020-07-10 武汉大学 II类V型CRISPR蛋白Lb2Cas12a及其在基因编辑的应用
CN110878290B (zh) * 2019-11-15 2022-03-18 武汉大学 II类V型CRISPR蛋白BfCas12a及其在基因编辑的应用
CN116042571A (zh) * 2021-05-26 2023-05-02 武汉大学 一种Cas12a变体及其在基因编辑中的应用

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2016106236A1 (en) * 2014-12-23 2016-06-30 The Broad Institute Inc. Rna-targeting system

Also Published As

Publication number Publication date
CN111235130A (zh) 2020-06-05

Similar Documents

Publication Publication Date Title
CN111235130B (zh) II类V型CRISPR蛋白CeCas12a及其在基因编辑的应用
CN107922931B (zh) 热稳定的Cas9核酸酶
CN110878290B (zh) II类V型CRISPR蛋白BfCas12a及其在基因编辑的应用
CN111394337A (zh) II类V型CRISPR蛋白Lb2Cas12a及其在基因编辑的应用
CN113136376B (zh) 一种Cas12a变体及其在基因编辑中的应用
CN105647943B (zh) 天山雪莲细胞鲨烯合酶基因SiSQS及其编码的产物和应用
CN113234701B (zh) 一种Cpf1蛋白及基因编辑系统
CN114410609B (zh) 一种活性提高的Cas蛋白以及应用
CN114480352B (zh) 一种碱性蛋白酶突变体及其用途
CN114672473A (zh) 一种优化的Cas蛋白及其应用
CN108865962B (zh) 一种可高效可溶性表达4-α-糖基转移酶的大肠杆菌工程菌
CN109152808A (zh) 用于核酸序列的特异性靶向的二聚蛋白质
CN113637658A (zh) 基于dCas9-oToV的基因转录系统及其应用
CN111944790B (zh) 中性蛋白酶基因、中性蛋白酶及其制备方法和应用
CN112961853A (zh) 基于C2c1核酸酶的基因组编辑系统和方法
CN115786305A (zh) 一种紧凑型编辑工具EbCas12a在基因编辑中的应用
CN108220255B (zh) 一种嗜热古细菌的高活性dna连接酶突变体
KR102358538B1 (ko) 유전자 총법을 이용한 미세조류의 교정 방법
CN114214308A (zh) 一种经半理性改造提升活性的腈水解酶突变体
CN115896070A (zh) 一种新型基因组编辑工具EbCas12a-D141R及其在基因编辑中的应用
CN106754768B (zh) 一种热稳定性提高的脂肪氧合酶突变体及其构建方法
CN112899255B (zh) Dna聚合酶及其应用、重组载体及其制备方法和应用、重组工程菌及其应用
JP2020092615A (ja) モノアシルグリセロールリパーゼ変異体及びその製造方法
CN114621944B (zh) 酶活提高的精氨酸脱亚胺酶突变体
RU2778156C1 (ru) Средство разрезания ДНК на основе Cas9 белка из бактерии Capnocytophaga ochracea

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
GR01 Patent grant
GR01 Patent grant